Understanding genetic and pharmacokinetic factors in post-ERCP pancreatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the genetic and pharmacokinetic factors that contribute to the risk of post-ERCP pancreatitis (PEP). It will involve collecting blood samples from patients who are scheduled to undergo endoscopic retrograde cholangiopancreatography (ERCP) to analyze potential risk variants. The study seeks to understand why some patients experience PEP despite preventive measures, such as the administration of rectal NSAIDs. By integrating pharmacokinetic data with genetic information, the research hopes to uncover underlying mechanisms that could inform better prevention strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* written informed consent
* Indication to undergo an ERCP

Exclusion Criteria:

* Pancreatic cancer
* Chronic pancreatitis
* Ongoing acute pancreatitis
* Altered anatomy, defined as anatomical variations in which gall and/or pancreatic juices (in case of pancreatic duct interventions) do not enter the duodenum by way of the ampulla of Vater.

Where it's running

• RadboudUMC
  Nijmegen, Gelderland, Netherlands Recruiting

Study contacts

• Principal investigator: Erwin van Geenen, MD, PhD — Radboud University Medical Center
• Study coordinator: Mike de Jong, MD
• Email: mike.dejong@radboudumc.nl
• Phone: 0031883207054

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Can a rectal NSAID alone prevent pancreatitis after ERCP instead of also placing a pancreatic duct stent?

  This trial will see if giving a rectal NSAID by itself prevents pancreatitis after ERCP in high-risk adults as well as giving both a rectal NSAID and a pancreatic duct stent.

  Recruiting at 11 sites Air Force Military Medical University, China · Beijing, Beijing Municipality and 14 other locations · NCT07117318

• Using intravenous fluids to prevent pancreatitis after ERCP procedures

  This study tests if different types of intravenous fluids can help prevent pancreatitis in patients undergoing ERCP procedures.

  Recruiting Phase 4 University of Calgary · Calgary, Alberta · NCT06260878

• Using Tacrolimus and Indomethacin to Prevent Pancreatitis After ERCP

  This study is testing if taking a medication called tacrolimus before a procedure to remove bile duct stones can help prevent pancreatitis in patients.

  Recruiting at 2 sites Phase 3 Johns Hopkins University · Baltimore, Maryland and 4 other locations · NCT05252754

• Short-stay aggressive hydration to prevent post-ERCP pancreatitis

  This trial tests whether a short, high-volume IV hydration with Lactated Ringer's plus a rectal indomethacin can prevent post-ERCP pancreatitis in adults undergoing ERCP.

  Recruiting Westmead Hospital · Westmead, New South Wales · NCT07776561

• Low-dose versus standard-dose indomethacin to prevent pancreatitis after ERCP

  This test sees if a lower rectal dose of indomethacin prevents pancreatitis as well as the standard 100 mg dose in adults undergoing ERCP.

  Recruiting at 3 sites Phase 4 Changhai Hospital · Shanghai and 11 other locations · NCT07088757

• Comparing early and late pancreatic stent placement to prevent post-ERCP pancreatitis

  This study is testing whether placing a pancreatic stent right after a procedure or later can help prevent pancreatitis in patients who have a difficult time with bile duct access.

  Recruiting The First Affiliated Hospital of Anhui Medical University · Hefei, Anhui and 1 other locations · NCT06250803

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.